No Data
No Data
INVO Bioscience Risks Nasdaq Delisting Amid Stock Price Woes
Express News | INVO Bioscience- Entered Fourth Amendment to Previously Announced Agreement & Plan of Merger by INVO Merger Sub and Naya Biosciences
INVO BioScience GAAP EPS of -$0.62, Revenue of $1.84M
Express News | INVO BioScience Q2 EPS $(0.62) Up From $(3.06) YoY; Revenue $1.826M Up From $315,902 YoY
INVO Bioscience | 10-Q: Q2 2024 Earnings Report
Express News | INVO Reports Record Second Quarter 2024 Financial Results With 481% Revenue Growth and a $1.1 Million Improvement to Adjusted Ebitda
No Data
No Data